Area of research
Infectious Diseases · Virology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, HIV Research and Treatment, HIV/AIDS drug development and treatment, and Monoclonal and Polyclonal Antibodies Research.
Generation of antigen-specific paired-chain antibodies using large language models
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
SARS-CoV-2 evolution in the Omicron era
Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses
Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study
Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
Frequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
Evasion of neutralising antibodies by omicron sublineage BA.2.75
Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies
Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies
Longitudinal single-cell analysis of SARS-CoV-2–reactive B cells uncovers persistence of early-formed, antigen-specific clones
SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses
Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Integrin α <sub>4</sub> β <sub>7</sub> expression on peripheral blood CD4 <sup>+</sup> T cells predicts HIV acquisition and disease progression outcomes
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
FUBAR: A Fast, Unconstrained Bayesian AppRoximation for Inferring Selection
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape